Review of the Antimicrobial Sales and Use (ASU) platform

The European Medicines Agency (EMA) launched the ASU platform in January 2024 to enhance the surveillance of antimicrobial use in animals and strengthen the EU’s fight against antimicrobial resistance (AMR). The first annual report for 2025 is expected to be published shortly.

Developed in line with the EU Veterinary Medicinal Products Regulation (Regulation (EU) 2019/6), the platform plays a key role in improving data collection, tracking trends, and informing policies on the prudent use of antimicrobials.

Since January 2024, EU/EEA member states must submit annual reports on the sales and use of antimicrobial medicinal products in cattle, pigs, chickens, and turkeys to the EMA.

This will include other poultry, sheep, goats, finfish, horses, rabbits, and other food-producing animals by 2027. By 2030, reporting will also cover non-food-producing animals, such as companion animals.

Impact on Marketing Authorization Holders

With EU/EEA national authorities now required to report antimicrobial sales and use, Marketing Authorization Holders (MAHs) must have robust systems to track and report data accurately. This should comply with EU standards.

The ASU platform is accessed via the Union Product Database (UPD), and all submissions must follow a standardized format. The EMA has issued guidance on the technical specifications, reporting protocols, and templates required for compliance.

As part of the EU’s broader AMR strategy, MAHs should prepare for increased regulatory scrutiny and ensure alignment with new antimicrobial stewardship requirements.

How G&L can help

Our veterinary medicine regulatory experts can help your company navigate these new requirements and achieve full compliance ahead of schedule.

Get in touch to learn how we can help you meet your deadlines with confidence – animalhealth@gandlscientific.com – or view our services here.

Dr. Sarah Hobson is Associate Manager of Regulatory Affairs at G&L Scientific.